CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.18 USD
-1.31 (-2.65%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $48.34 +0.16 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRSP 48.18 -1.31(-2.65%)
Will CRSP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Other News for CRSP
Disc Medicine appoints Caffe as CRO
Crispr Therapeutics: Prepare To Be Bored
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Oruka announces closing of merger with ARCA Biopharma
How major US stock indexes fared Wednesday, 8/28/2024